amlodipine vitabalans 10 mg tabletes
vitabalans oy, finland - amlodipīns - tablete - 10 mg
agen 10 mg tabletes
zentiva, k.s., czech republic - amlodipīns - tablete - 10 mg
amlodipine medochemie 10 mg tabletes
medochemie ltd., cyprus - amlodipīns - tablete - 10 mg
amlodipine medochemie 5 mg tabletes
medochemie ltd., cyprus - amlodipīns - tablete - 5 mg
priamlo 8 mg/5 mg tabletes
zentiva, k.s., czech republic - perindoprili erbuminum, amlodipinum - tablete - 8 mg/5 mg
priamlo 4 mg/5 mg tabletes
zentiva, k.s., czech republic - perindoprili erbuminum, amlodipinum - tablete - 4 mg/5 mg
priamlo 4 mg/10 mg tabletes
zentiva, k.s., czech republic - perindoprili erbuminum, amlodipinum - tablete - 4 mg/10 mg
priamlo 8 mg/10 mg tabletes
zentiva, k.s., czech republic - perindoprili erbuminum, amlodipinum - tablete - 8 mg/10 mg
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiskie līdzekļi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
qaialdo
nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 un 5.